-
Advenchen Lab’s AL8326 and Hengrui’s SHR-A1811 Receive Breakthrough Therapy Designations
•
The Center for Drug Evaluation (CDE) website indicates that Advenchen Lab’s AL8326 and Hengrui Pharmaceuticals’ (SHA: 600276) SHR-A1811 have been awarded separate breakthrough therapy designations (BTDs). This recognition highlights the potential of both drugs to significantly improve the treatment of cancer patients. Advenchen’s AL8326: A Promising TKI InhibitorAdvenchen’s drug candidate…
-
Merck & Peking University Launch Public Health Training Projects for Young and Middle-Aged Talent
•
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and the Peking University School of Public Health have officially initiated public health projects aimed at training young and middle-aged backbone talent. This collaboration seeks to enhance the skills and knowledge of professionals in the public health sector, contributing to the development…
-
Biokin’s BL-B01D1 Receives NMPA Approval for Phase II Solid Tumor Study
•
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study assessing the efficacy and safety of its drug candidate BL-B01D1 as a treatment for solid tumors. The study will evaluate the…
-
Junshi Biosciences’ JS010 Receives NMPA Approval for Migraine Clinical Trials
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its JS010, an in-house developed CGRP-targeted monoclonal antibody (mAb) drug candidate for the treatment of migraines. CGRP and Its Role in MigrainesCGRP is a neuropeptide composed…
-
Immunotech Biopharm’s CAR-T-19-D2 Receives NMPA Approval for DLBCL Clinical Trial
•
China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its CAR-T-19-D2 (CAR-T-19-DNR or RC19D2) in recurrent/refractory diffuse large B-cell lymphoma (DLBCL). Mechanism of Action and Clinical NeedCAR-T-19-D2 targets the CD19…
-
Smith & Nephew Partners with MedMotion for Digital Health Innovation
•
UK-based Smith & Nephew Plc has announced a strategic partnership with China’s Shanghai Fudong Medical Management Co., Ltd, also known as MedMotion, a leading digital health company. This collaboration aims to enhance digitalization innovation and explore comprehensive “pre-operative, intraoperative, and post-operative” perioperative management solutions. Aim to Revolutionize Post-Operative RehabilitationThe partnership…
-
Aidea Pharma and China Meheco Partner to Expand Medical and Pharmaceutical Services
•
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced a partnership with China Meheco International Co., Ltd, a wholly-owned subsidiary of China Meheco Group Co., Ltd. The collaboration will focus on project cooperation and investment, leveraging the comprehensive advantages of both companies in information, knowledge, talent, products, and channels…
-
3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials
•
China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859 billion (USD 995.9 million), a 7.5% increase year-on-year (YOY). Net profits reached RMB 2.163 billion (USD 314 million), up 25.2% YOY. This marks a significant milestone in the company’s ongoing growth and expansion. Core Product…
-
Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000
•
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with compatriot firm TaiGen Biotechnology Co., Ltd. Under the terms of the agreement, Joincare will take exclusive development, manufacturing, and commercialization rights to TaiGen’s PA endonuclease inhibitor TG-1000, as well as its derivatives, in the Greater…
-
Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study
•
Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in 2018, has released interim data from the 16-week mark in the Phase III QUARTZ3 study. The study is assessing the efficacy of the JAK1 inhibitor ivarmacitinib in patients with moderate to severe atopic dermatitis (AD).…
-
Sinopharm Forms Joint Ventures with Foreign Medical Equipment Firms
•
Sinopharm China National Biotech Group Co., Ltd (CNBG) has announced partnerships with two foreign medical equipment firms to set up joint ventures (JVs) with majority stakes controlled by the state-owned company. This strategic move aims to enhance Sinopharm’s capabilities in the medical equipment sector. Radiotherapy and Imaging Joint VenturesSinopharm’s subsidiary,…
-
BeiGene Marks Topping Off of New Biologics Facility in New Jersey
•
China-based biotech BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) held a ceremony to mark the “topping off” of construction at its new biologics manufacturing and R&D facility in Hopewell, New Jersey. The last piece of structural steel was laid at the site, signaling that construction is now expected to be…
-
Roche Partners with China Resource Medicine to Promote Xofluza in China
•
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into a partnership with China-based China Resource Medicine Commercial Holdings Ltd to jointly promote the anti-influenza drug Xofluza (baloxavir marboxil) in China. Under the agreement, Roche will continue to handle channel promotion for the drug in major hospitals, while CR Medicine Commercial…
-
Jacobio Pharma Partners with Merck to Evaluate CD73 mAb and Keytruda Combination
•
China-based Jacobio Pharma (HKG: 1167) has announced a clinical partnership with Merck, Sharp & Dohme Inc. (NYSE: MRK) to assess the clinical effects of Jacobio’s CD73 monoclonal antibody (mAb) JAB-BX102 combined with Merck’s PD-1 inhibitor Keytruda (pembrolizumab) in advanced solid tumors. No financial details were disclosed in the partnership agreement.…
-
Yifan Pharmaceutical’s F-652 Cleared for Phase II Trial in Alcoholic Hepatitis
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary Evive Biotech Ltd’s F-652 has been cleared to start a Phase II clinical trial for a new indication by China’s National Medical Products Administration (NMPA). The trial will assess F-652 as a treatment for alcoholic hepatitis (AH). Mechanism…
-
BioNTech Acquires Global Rights to OncoC4’s Anti-CTLA-4 Antibody ONC-392
•
Germany-based mRNA specialist BioNTech SE (NASDAQ: BNTX) has unveiled a licensing deal and collaboration with US-based biotech OncoC4, securing global development and commercialization rights to OncoC4’s anti-CTLA-4 antibody ONC-392. Under the terms of the agreement, BioNTech will pay OncoC4 USD 200 million upfront, with further undisclosed development and commercial milestone…
-
Cygnus Bio Raises Millions in Series C+ Financing for Sequencing Technology
•
Beijing-based second-generation sequencing technology platform Cygnus Bio has reportedly raised “hundreds of millions” of renminbi in a Series C+ financing round. The round was led by Source Code Capital, with contributions from CCB Private Equity Investment, E-town Capital, Founder H Fund, and Lotus Lake Capital. The funds will be used…
-
L&L Biopharma Completes Series B Financing for Tumor Immunotherapy Development
•
Shanghai-based tumor immunotherapy developer L&L Biopharma Co., Ltd has announced the completion of a Series B financing round, led by Hongfeng Venture. Additional investors included Oriental Wisdom Capital, Zhongchuang Yongjian (Ningbo) Venture Capital, and existing investor Qiao Jing Capital. The funds will be directed towards Phase I clinical studies for…
-
T&L Biotechnology Secures RMB 100 Million in Series A Financing
•
Beijing-based cell and gene therapy (CGT) developer T&L Biotechnology Co., Ltd has reportedly raised RMB 100 million (USD 14.53 million) in a Series A financing round. The round was led by Harvest Capital and Fortune Capital, with participation from Zhiheng (Yantai) Entrepreneurship Service Center. The funds will be used to…
-
Yiling Pharmaceutical’s BIO-008 Receives NMPA Approval for Clinical Trials
•
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its novel biologic product BIO-008. This marks a significant milestone in the development of the company’s innovative therapeutic biologic. Development and IndicationsBIO-008 is a monoclonal antibody…
